Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.51 |
| ▸ | INSR | P06213 | 4/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709590 | 0.86 | ALK (0.42) | ALKINSRIGF1R | |
| SCHEMBL19288567 | 0.84 | ALK (0.49) | ALKINSRLRRK2IGF1R | |
| SCHEMBL11916339 | 0.83 | ALK (0.55) | ALKINSRLRRK2IGF1R | |
| SCHEMBL17527347 | 0.80 | ALK (0.47) | ALKINSRLRRK2 | |
| SCHEMBL11900440 | 0.80 | ALK (0.47) | ALKINSR | |
| SCHEMBL17527454 | 0.76 | ALK (0.59) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL11901898 | 0.76 | ALK (0.59) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL11901894 | 0.76 | ALK (0.59) | ALKINSRLRRK2JAK2SRC | |
| SCHEMBL11900492 | 0.68 | ALK (0.54) | ALKINSRLRRK2IGF1R | |
| SCHEMBL11916333 | 0.67 | ALK (0.60) | ALKINSRLRRK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885LRRK2 652/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | ALK 256/4885INSR 941/4885LRRK2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.